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Prolongation of canine allograft survival with donor pretreatment.
Donor pretreatment of 100 mg/kg each of cyclophosphamide (CY) and
methylprednisolone (P) infused 5 hours before nephrectomy invariably
prolongs the survival of DLA mismatched, MLC incompatible non-
littermate Beagle renal allografts as well as the survival of mongrel renal
allografts. The effect of donor pretreatment appears to be mediated by
cyclophosphamide and its metabolites because methylprednisolone
pretreatment does not significantly prolong survival. Methyipredniso-
lone is needed, however, because it abolishes cyclophosphamide pre-
treatment mediated early but transient postoperative renal (allograft)
insufficiency. The effect of donor pretreatment appears to be mediated
by drugs residing in the graft; mannitol infusions given 1 hour prior to
donor nephrectomy or peroperatively into the recipient decrease the
renal cortical content of carbon 14 cyclophosphamide and its metabo-
lites and abolishes the prolonged survival. Because donor pretreated
kidneys contain less than 0.5% of the infused dose of carbon 14
cyclophosphamide, the drugs appear to exert their effect locally in the
transplanted kidney. Donor pretreatment mediating prolonged canine
renal allograft survival appears to be an example of influencing a
biological process by a localized drug delivery by virtue of unique
properties of the drug and because early postoperatively host sensitiza-
tion occurs mainly at the site of the graft.
Prolongation de l'allogreffe survie chez le chien au moyen du pre-
traitement du donneur. Le pré-traitement du donneur (des 100 mg/kg de
chaque drogue) au moyen de cyclophosphamide (CY) et de methyl-
prednisolone (P) perfusés en 5 heures avant Ia néphrectomie, prolonge
dans tous les cas Ia survie d'allogreffes rénales chez des chiens Beagle
n'appartenant pas a Ia méme portée, MLC incompatibles, DLA non-
identiques. De mCme Ia survie de l'allogreffe rénale est allongée chez le
chien bâtard. L'effet du pré-traitement du donneur parait avoir pour
médiateurs le cyclophosphamide et ses métabolites parce que le pré-
traitement par Ia methyiprednisolone ne modifie pas significativement
Ia survie de Ia greffe. La methyiprednisolone est cependant nécessaire
parce qu'elle abolit l'insuffisance rénale transitoire précoce de Ia greffe,
elle-méme dépendante du cyclophosphamide. L'effet du pré-traitement
du donneur paralt avoir pour médiateurs des drogues presentes dans Ia
greffe; Ia perfusion de mannitol, administrée une heure avant Ia
nephrectomie ou au receveur, diminue le contenu renal cortical en
carbone 14 cyclophosphamide et en ses métabolites et abolit l'allonge-
ment de Ia survie. Dans Ia mesure oi les reins pré-traités contiennent
moms de 5% de la dose de carbone 14 cyclophosphamide perfuse, les
drogues paraissent exercer leur effet localement dans le rein trans-
plante. L'allongement de Ia survie de l'allogreffe rénale de chien au
moyen du pré-traitement du donneur parait être un exemple de Ia
modification d'un processus biologique par Ia délivrance locale d'une
drogue en fonction des propriétés remarquables de Ia drogue et du fait
que Ia sensibilisation de l'hôte survient dans Ia phase post-opératoire
précoce essentiellement au lieu de Ia greffe.
Clinically prolonged allograft survival is brought about by
modulating the immune response of the host together with
attempts to reduce immunogenicity by means of tissue typing or
donor pretreatment using large dosages of cyclophosphamide
and methylprednisolone [1]. The rationale for donor pretreat-
ment derives from studies in rats which suggested that leuko-
cytes were immunogenic to allogeneic hosts [21!. The observa-
tion that depletion of peripheral blood leukocytes of the donor
(by lethal x-irradiation with 1200 rad administered 2 to 4 days
prior to donor nephrectomy) enhanced the survival of renal
allografts in the rat and dog by means of a systemic effect on the
donor, and not by a local effect on the graft [3], confirmed the
immunogenecity of passenger leukocytes. Precisely how pas-
senger leukocytes sensitize the host is unclear, but lymphocytes
residing in the interstitial tissue [4] of the kidney have been
shown to be capable of migrating out of a renal allograft within
24 hours postoperatively in order to relocate in the central
lymphoid tissue of the host [51; there they may sensitize the
host because they share class I alloantigens [61 and Ia-like
alloantigens [7] with the endothelial cells of the renal graft or,
alternatively, they may amplify the host versus graft response
by a proliferative reaction directed against the host [8].
Since reduction of renal graft immunogenecity by means of
lethal x-irradiation of the cadaver donor is not feasible clinically
because of the 48-hour interval needed to bring about leukocyte
depletion and because lethal x-irradiation may damage the
kidney irreversibly, [9] pharmacological reduction of graft
immunogenecity by pretreating cadaveric donors with massive
dosages of cyclophosphamide and methylprednisolone was
introduced in 1973 [10]. This strategy was derived from studies
in rats which showed that dosages of cyclophosphamide suffi-
cient to cause leukocytopenia and to abolish the proliferative
capacity of lymphocytes in vitro [111 enhanced the survival of
kidneys [12] and hearts [13, 14] transplanted over a strong
histocompatibility locus. In man the effectiveness of donor
pretreatment with massive dosages of cyclophosphamide and
methylprednisolone is a controversial issue for the prolonged
survival observed in two uncontrolled series consisting of a
large numbers of patients [15, 16] was not confirmed in another
study consisting of a small number of patients [17] nor observed
in a controlled study using randomization of patients [18].
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Because the rat differs from man in terms of cyclophosphamide
metabolism [19], the lack of a consistent effect of donor
pretreatment on cadaveric renal allograft survival need not only
be due to differences in protocol, but may also pertain to
specific differences in the way each species handles cyclophos-
phamide.
Our study addresses itself to the reduction of the first set of
renal allograft immunogenecity in dogs by means of donor
pretreatment with cyclophosphamide and methyiprednisolone
because dogs resemble man both in terms of cyclophosphamide
metabolism [19] and relative resistance to the effect of cortico-
steroids [201. In the dog a 5- to 6-hour period of donor
pretreatment with dosages of cyclophosphamide and methyl-
prednisolone sufficient to cause clearcut leukocytopenia [20]
has been reported to prolong the survival of pretreated kidneys
inserted into unmodified [21] and immunosuppressed [201 hosts.
Others, however, failed to observe an effect of donor pretreat-
ment with cyclophosphamide and methylprednisolone above
that of methylprednisolone alone [221, and some observed an
adverse effect of donor pretreatment on the first set of canine
renal allograft survival [23]. In all of the canine studies mongrels
were used, and consequently, the histocompatibility barrier
crossed was not known nor could individual specific differences
in hepatic activation of cyclophosphamide [241 be taken into
account. Therefore, the effect of donor pretreatment with
dosages of cyclophosphamide and methylprednisolone known
to abolish a proliferative capacity of human lymphocytes in
vitro [25] and reported to be effective clinically [15] was
assessed in a rigidly standardized protocol using tissue type
mismatched inbred Beagles. Because donor pretreatment pro-
longed the survival of these renal allografts, we next evaluated
the effect of donor pretreatment on mongrel renal allografts and
addressed ourselves to the question of whether or not donor
pretreatment mediated prolonged canine renal allograft survival
was brought about by means of an effect on passenger leuko-
cyte or alternatively was mediated by passive transfer of drugs,
specifically cyclophosphamide metabolites, residing in the kid-
ney at the time of transplantation.
Methods
Animals. Donor kidneys were harvested from mongrel dogs
or from inbred, tissue typed and for the recipient mismatched
non-littermate Beagles depending on the nature of the experi-
ment. When non-littermate Beagle combinations were used,
they were tissue typed serologically for DLA antigens [26] and
also in a unilaterally mixed leukocyte culture (MLC) [27] with
standard techniques by A. B. Bijnen, M.D., Department of
Surgery, Erasmus University, Rotterdam, The Netherlands.
Donor and recipient Beagle combinations were chosen in such a
fashion that they differed from each other by at least one
serologically defined DLA haplotype and also stimulated in
unilateral MLC [281. The donor provided the stimulator cells (in
the unilateral MLC) and the recipient the responder cells.
Unmodified non-littermate Beagle renal allografts mismatched
in this fashion are rejected within 11 days [28]. Mongrels were
not tissue typed for the effect of matching for serologically
defined DLA-A, B, and C antigens; MLC has far less influence
on mongrel renal allograft survival compared to littermate as
well as non-littermate Beagle renal allograft survival [28, 29].
Mongrel dogs were selected using the criteria of good health,
age [30], and normal renal function as shown by preoperative
serum creatinine concentrations below 100 j.moles/liter. Both
male and female dogs were used between 1 and 4 years of age.
All recipients were inbred Beagles varying in weight between 9
and 14 kg. None of the recipients had been sensitized by blood
or pregnancy.
Surgery. After removal of the donor kidneys by median
laparotomy, kidneys were perfused ex vivo with ISO ml of a
slightly modified sterile Collins C2 solution at 4° C using a
waterhead of 100 cm; perfusion duration varied from 8 to 10
mm. Kidneys which perfused poorly—duration of perfusion
over 15 mm—were discarded. After perfusion the kidneys were
stored in the Collins solution on melting ice up to 1 hour, after
which they were grafted into the recipient. Kidneys were
grafted into the right iliac fossa of bilaterally nephrectomized
recipients. Warm ischemia time varied from 17 to 25 mm with a
mean of 22 mm. Transplantations were considered successful
when the serum creatinine concentration was below 200
.u.moles/liter on the second day postoperatively. Grafts were
considered to be rejected when the serum creatinine concentra-
tion increased progressively to 1000 i.moles/liter or when the
recipient died because of uremia. All recipients were autopsied
and rejection was confirmed macroscopically and microscopi-
cally.
Donor pretreatment. After the induction of fluothan anesthe-
sia, 100 mg/kg each of cyclophosphamide (CY) and methyl-
prednisolone (P) were infused separately or together as a bolus
i.v. Dogs were kept under light anesthesia up to the moment of
nephrectomy. The dosages of drugs chosen were identical to
those used clinically [15]. The duration of donor pretreatment
with CY and P necessary to bring about enhanced renal
allograft survival was determined in preliminary experiments. A
3-hour period of donor pretreatment with CY and P failed to
prolong the survival of three DLA mismatched, MLC incom-
patible inbred Beagle renal allografts; the survival times of 9,
11, and 11 days did not differ significantly P < 0.5 from the
mean survival of 9 1.8 days of unmodified controls, but a 5-
hour period of donor pretreatment with CY and P caused
invariably enhanced renal allograft survival (see Results). A 5-
hour period of donor pretreatment with CY and P decreased the
peripheral blood lymphocytes to 25% of the original value and
abolished proliferative capacity in unilaterally mixed leukocyte
cultures performed as described elsewhere [31].
Mannitol. Mannitol, 5 mg/kg of a 20% solution, was infused
i.v. over a 20-mm period into the donor 60 mm prior to
nephrectomy or preoperatively into the recipient after revascu-
larization of the transplant. In the donor diuresis was monitored
by an indwelling catheter; diuresis increased usually 10 to 20
times after the mannitol infusion. An amount of 5% glucose
equal to the mannitol-induced osmotic diuresis was infused i.v.
Carbon 14 cyclophosphamide. Radioactivity cyclophospha-
mide monohydrate (ring-4-'4C) with a specific activity of 250
mCi per 6.2 mg of cyclophosphamide was purchased from New
England Nuclear Co., Boston Massachusetts. Mongrel dogs,
weighing 9 to 10 kg, were infused with radioactive cyclophos-
phamide, 10 to 25 p.Ci/kg, together with cold CY and P, 100 mgI
kg, each 5 hours prior to sacrifice as a bofus i.v. At the time of
sacrifice one or both kidneys were perfused as described above.
Depending on the protocol, the left kidney was transplanted.
The perfused right kidney was sliced into 5 mm pieces perpen-
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Table 1. The effect of donor pretreatment on the survival of inbred
and mismatched Beagle renal allografts'
Beagle renal allograft survivat in days
No. experiment
postoperatively
Unmodified Pretreated
1 10 18
2 8 15
3 9 16
4 11 20
5 6 16
6 10 18
Mean SD 9 1.8 17 1.8
a Non-littermate Beagles were chosen on the basis of tissue typing in
such a fashion that one donor differed at least one DLA haplotype from
each of two recipients and also stimulated in MLC. The donor was
infused with 100 mg/kg of cyclophosphamide and methylprednisolone
after the removal of one kidney; the remaining kidney was harvested 5
hrs later. Both the unmodified and "pretreated kidney" were trans-
planted in each of two recipients. Renal allografts were considered
irreversibly rejected when the recipient died because of uremia or the
serum creatinine concentration exceed 1000 l.Lmoles/liter.
dicular to the long axis; next the slices were divided into
subcapsular renal cortes with a capsule, mid and inner renal
cortex, and medulla and papilla. Multiple 0.5 g tissue pieces
were taken from the inner and mid cortex, medulla and papilla,
sealed in plastic, and frozen at —20° C. To determine total renal
radioactivity, we stripped perfused kidneys of the capsule,
hilus, and ureter which were individually weighed and sealed as
described above. Next the decapsulated kidneys were sliced
and divided into compartments; 0.5 g tissue aliquots from the
outer cortex, mid and inner cortex, papilla, and medulla were
taken and stored at —20° C. Aliquots of serum, urine, and non-
perfused extrarenal organs were also sealed and frozen. In
order to avoid color quench, aliquots of tissue or 0.1 to 0.25 ml
of urine, bile or serum were absorbed on paper and burned in a
sample oxidizer oven, model 306 (Packard International Co.,
Brussels, Belgium). The '4C02 was collected into Carbosorb
TM and Perma Iluor V (Packard International Co., Brussels,
Belgium). Samples were counted in a liquid scintillation counter
using the external standard for counting efficiency.
Lymph node cells. Lymph node lymphocytes were prepared
by mincing lymph nodes—removed surgically prior to the
infusion of CY and P into the donor—and pressing the mince
through five layers of nylon into a minimally essential medium
containing 5% heat inactivated calf serum. The cells were next
centrifuged on Ficoll/Hypaque, density 1077, and those cells in
the interphase were harvested. These lymphocytes were over
90% viable by trypan blue exclusion.
Statistics. The survivors of the renal allografts were com-
pared by the Wilcoxon mid rank sum test [32].
Results
The effect of donor pretreatment on canine renal a/b graft
survival. The effect of donor pretreatment with 100 mg/kg each
of cyclophosphamide (CY) and methylprednisolone (P) was
first assessed using tissue-typed Beagles in sets of three. One
Beagle donated one unmodified and one pretreated kidney to
each one of two nonlittermate Beagle recipients who differed
from the donor by at least one DLA haplotype and also had
proliferated in a mixed leukocyte culture. After the removal of
one kidney, the donor received CY and P i.v. The "pretreated"
kidney was harvested 5 hours later. Six experiments were
performed (Table 1): Donor pretreated renal allografts survived
17 1.8 days which is about twice the survival of unmodified
renal allografts and highly significant (P < 0.0011). When
mongrel dogs were used in lieu of Beagles as donors, the
pretreated kidneys also enjoyed a prolonged survival of 17
3.2 days (Table 2) which was twice the survival rate of
unmodified mongrel renal allografts (8.3 2.0 days) and also
highly significant (P < 0.0002). In order to decide whether or
not the prolonged survival was brought about by CY and P or
both, mongrel dogs were pretreated with 100 mg/kg of CY or P.
After 5 hours of pretreatment, these kidneys were transplanted
into Beagle recipients. Methylprednisolone pretreated mongrel
renal allografts survived for 10.6 4.3 days which is not
significantly (P < 0.2) different from the survival of unmodified
mongrel renal allografts. Cyclophosphamide pretreated mon-
grel renal allografts on the other hand showed a significantly (P
<0.005) prolonged survival of 15.4 2.3 days. All cyclophos-
phamide pretreated renal allografts (Fig. 1), however, experi-
enced an episode of early postoperative renal insufficiency as
shown by a serum creatinine concentration above 200 p.moles/
liter on the second day postoperatively in every instance. The
serum creatinine concentrations decreased in all recipients
subsequently and were below the 150 moles/liter in four out of
five recipients within 7 days postoperatively. Operationally
therefore, all cyclophosphamide pretreated renal allografts had
to be considered as 'technical failures". Nevertheless, the
effect of donor pretreatment appeared to be mediated by
cyclophosphamide and its metabolites.
On the mechanism of donor pretreatment. If the effects of
donor pretreatment were to be mediated by passenger leuko-
cytes, the passive transfer of viable lymphocytes from the
donor into the recipients of donor pretreated renal allografts
might abolish the prolonged survival. Therefore, l0 viable
lymph node lymphocytes harvested from the donor before
pretreatment with CY and P were infused into Beagle recipients
of pretreated DLA mismatched and MLC incompatible non-
littermate Beagle kidneys. The number of lymph node cells
used were derived from rat experiments [5] which showed a l-g
rat kidney to contain about 106 lymphocytes of which 5% were
"mobile" and capable of migrating out of the renal transplant in
order to relocate into the spleen of the allogeneic host within 24
hours postoperatively. A 30-g dog kidney was therefore consid-
ered to have no more than 1.5 x 106 "mobile" passenger
lymphocytes capable of relocating into an allogeneic spleen.
The passive transfer of l0 lymph node cells (30% of which may
be taken to relocate into an allogeneic spleen [5]) intravenously
into the recipient of a pretreated renal allograft did not abolish
the enhanced survival in two experiments as shown by survival
times of 20 and 19 days; also infusion of l0 autologous lymph
node cells into the renal artery of the pretreated transplant
immediately after revascularization failed to influence the effect
of donor pretreatment as shown by survival times of 20 and 16
days in two experiments.
These experiments suggested that the effect of donor pre-
treatment might not be caused by an effect on passenger
leukocytes but rather by drugs residing in the donor pretreated
kidney. Because the urinary excretion of cyclophosphamide
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Table 2. Effect of mannitol infusions on the survival of donor pretreated canine renal ailografts
No. exp.
Donor pretreatment
Recipient
pretreatment
M
.RAS in days
postoperatively5CY P M
6 — — — — 8.3+2.1
11 + + — — 17.0±3.1
6 + + + — 7.2±1.5
5 + + — + 8.2±2.2
Mongrel dogs were given 100 mg/kg iv. of both cyclophosphamide (CY) and methyiprednisolone (P); their kidneys were harvested 5 hrs later,
perfused with 150 ml cold Collin's solution and transplanted into Beagle recipients. Mannitol (M), 5 mi/kg of a 20% solution, was infused into the
donors 1 hr prior to nephrectomy and into the recipients preoperatively after revascularization of the renal allograft.
b Mean SD
Abbreviation used is defined: RAS, renal allograft survival.
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mongrel kidneys immediately after revascularization of the
transplant. Mannitol infusions given to the recipient also abol-
ished the effect of donor pretreatment on renal allograft survival
(Table 2).
The cyclophosphamide content of pretreated kidneys. In
order to decide whether or not cyclophosphamide and its
metabolites transplanted within the donor-pretreated kidney
exerted a systemic effect on the host or a local effect in the renal
aliograft, the dose of cyclophosphamide and metabolites trans-
planted was measured by infusing 10 to 25 p.Ci/kg of carbon 14
cyclophosphamide together with 100 mg/kg each of cold CY
and P into the donor, Well perfused donor-pretreated kidneys
contained about 0.5% of the infused dose of cyclophosphamide.
The concentration of radioactive carbon in the renal cortex
exceeded that of the medulla. Mannitol infusions given 60 mm
prior to donor nephrectomy decreased the renal cortical con-
centration of carbon 14 and reduced the transplanted dose by
over 50% (Table 3).
F Additional evidence that mannitol decreased the renal con-
tent of cyclophosphamide was obtained by transplanting two
• donor-pretreated kidneys from mongrels with comparable
7 amounts of radioactive carbon into two recipients, one of which
received mannitol peroperatively (Table 4). Both donor-pre-
treated kidneys enjoyed a good and comparable renal function
as shown by an identical diuresis in the first hour postoperative-
ly. At the time of sacrifice at two hours postoperatively, the
renal graft residing in the mannitol infused recipient contained
less than half of the radioactivity that the control renal allograft
had. In the mannitol-infused recipient 63% of the transplanted
renal radioactivity was recovered in liver and bile; on the other
hand, in the control renal allograft 76% of the transplanted dose
was recovered from a urine sample and a renal transplant.
5
Fig. 1. The effect of donor pretreatment on early renal allograft
function. Unmodified (0) and donor-pretreated mongrel kidneys were
transplanted into Beagle recipients. Donor pretreatment consisted of
cyclophosphamide (•) or cyciophosphamide and methylprednisolone(E) 100 mg/kg each infused 5 hrs prior to donor nephrectomy. The
symbols designate the following: 0: N = 6 up to the sixth day
postoperatively and N = Son the seventh day; N = 5; ON = 11. The
meansof the serum creatinine concentration and one standard deviation
are given.
metabolites is influenced by diuresis [19], attempts were made
to flush putative cyclophosphamide metabolites out of CY- and
P-pretreated mongrel kidneys by infusing mannitol, 5 mI/kg of a
20% solution i.v., into the donor 1 hour prior to nephrectomy.
Mannitol was chosen because of its diuretic properties and
because it may ameliorate ischemia mediated postoperative
perturbation of renal function [33]. Mannitol infusion abolished
the effect of donor pretreatment on renal allograft survival
(Table 2). Additional support for the hypothesis that the effect
of donor pretreatment was mediated by drugs residing in the
transplant was obtained by infusing mannitol, 5 mg/kg of a 20%
solution i.v., into Beagle recipients of CY- and P-pretreated
Discussion
Donor pretreatment with cyclophosphamide and methyl-
prednisolone caused an almost two-fold prolonged survival of
DLA mismatched MLC incompatible, non-littermate Beagle
renal allografts in a controlled series of experiments in every
instance. The effect of donor pretreatment on renal allograft
survival was not restricted to the Beagle strain because donor
pretreatment caused enhanced survival of mongrel renal allo-
grafts equal to that observed in non-littermate and mismatched
Beagles. It is unlikely that this degree of prolonged survival is
brought about exclusively by an effect on passenger leukocytes
because destruction of passenger leukocytes by lethal total
1R
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Table 4. Effect of preoperatively administered mannitol on the carbon 14 cyclophosphamide residing in donor-pretreated canine renal allografts"
Diuresis jb
mi/hr
Radioactivity in % of transplanted dose
Renal medulla Whole
Kidney Renal cortex" and papilla renal Liver and
no. Mannitol 1st 2nd / g I g transplant Urine" bile
2B — 17.5 14 1.19 0.44 25.59 51.12 13.06
3B + 17.0 49 0.41 0.21 10.05 17.11 63.73
Two donor pretreated and well perfused kidneys containing 0.425% (2B) and 0.496% (3B)of the dose of carbon 14 cyclophosphamide were
transplanted. Mongrel dogs and recipients weighed between 9 and 10kg. After revascularization mannitol, 20% 5 mI/kg, was infused i.v. into the re-
cipient of one donor-pretreated kidney. A urine sample was collected by means of an indwelling catheter. Recipients were sacrificed 2 hrs after
transplantation when the bile was harvested. All radioactive values given represent the mean of two different pieces of tissue or aliquots of urine
and bile.
b Diuresis in the first and second hour postoperatively.
"Mid cortex.
d Radioactivity of the two-hour urine volume.
Radioactivity of the entire liver and bile.
body X-irradiation of donor dogs 96 hours before nephrectomy
prolongs the survival of these grafts by three days only [31. The
observation that passive transfer of iO viable donor lymph
node cells i.v. into recipients of donor pretreated Beagle renal
allografts or into recipients of donor-pretreated allografts after
revascularization failed to influence the effect of donor pretreat-
ment may be taken as another argument against the effect of
donor pretreatment being mediated by mobile passenger leuko-
cytes. There are good reasons to assume that the effect of donor
pretreatment is mediated by drugs residing in the graft at the
time of surgery, particularly cyclophosphamide and its metabo-
lites. First methyiprednisolone pretreatment enhanced the sur-
vival of only one out of five mongrel renal allografts which was
not statistically significant. Donor pretreatment with cyclo-
phosphamide on the other hand enhanced the survival of
mongrel renal allografts significantly, but all renal allografts
went through an episode of early and transient postoperative
uremia.
Because chronic uremia in men may be associated with a
markedly prolonged survival of cadaveric renal allografts in one
of the earlier reported series [34J and because chronic uremia
interferes with an acute rejection of cardiac allografts in the rat
[35], we cannot rule out that the episode of transient uremia
contributed to the enhanced survival of cyclophosphamide
pretreated renal allografts. Also, because of cyclophosphamide-
mediated nephrotoxicity, the effect of cyclophosphamide pre-
treatment in renal allograft survival can only be accurately
assessed in conjunction with methylprednisolone pretreatment,
for methylprednisolone protects the kidney both against ische-
mia [36] and cyclophosphamide-mediated injury.
Second, the fact that mannitol infused 1 hour prior to donor
nephrectomy or peroperatively into the recipient abolished the
effect of donor pretreatment on renal allograft survival and
decreased the dose of cyclophosphamide and/or its metabolites
in the graft, particularly in the renal cortex, indicates that the
effect of donor pretreatment is mediated by drugs residing in the
renal allograft. The failure of others to observe an effect of
pretreatment with cyclophosphamide on canine renal allograft
survival [221 and of pretreatment with cyclophosphamide and
methylprednisolone on cadaveric renal allograft in men [181
may be due to the fact that in the first study mannitol was
infused into the recipient and in the second study into the
pretreated donor prior to nephrectomy. Cyclophosphamide is
converted by the liver and much less so by the kidney [37J into
watersoluble active and inactive metabolites which are excreted
into the bile and by means of glomerular filtration into the urine
Table 3. Effect of mannitol infusion on the carbon 14-cyclophosphamide content of donor pretreated canine renal allografts"
Exp.
no. Mannitol
Radioactivity per
in '/oo of infused
I g of kidney
dose
Medulla and papilla TRR"Cortex"
+
+
Five dogs were given 100 mg/kg i.v. of both Cy and P in a bolus containing 10 to 20 C C/kg of carbon 14 cyclophosphamide 5 hrs prior to
nephrectomy. When desired mannitol, 20% 5 mI/kg, was infused 60 mm prior to sacrifice. Kidneys were perfused with 150 ml of a cold Collin's so-
lution prior to processing. From dogs 2 and 3 the left kidney was transplanted; the right kidneys (R) were used for measuring renal radioactivity.
b The mean radioactivity expressed per gram of tissue of two 0.5 g pieces of mid and inner cortex, and medulla and papilla is given. Variation
from the mean was less than 15% for the renal cortex and less than 20% for the medulla/papilla.
"Total renal radioactivity (TRR): The radioactivity of I g of renal outer and inner cortex, medulla and papilla, renal capsule, perirenal fat, and
ureter was multiplied with the total weight of each tissue. Next all radioactivity was added.
"N.D. means "not done."
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[381. The urinary excretion of metabolites is influenced by
diuresis [191; the renal tubu]es have been shown to be capable
of reabsorbtion [39}. Because the donor pretreated kidneys
were perfused with 150 ml of Coltin's solution, it is reasonable
to assume that most of the intratublar load of water soluble
metabolites was removed and that mainly cyclophosphamide
and metabolites residing in renal parenchymal cells and intersti-
tial tissue were transplanted.
How mannitol flushes cyclophosphamide metabolites out of
the kidney we do not know; this need not be by diuresis because
of two observations. In preliminary experiments we have
observed in donor-pretreated mongrel dogs that a furosemide-
induced diuresis initiated 60 mm prior to nephrectomy does not
abolish the effect of donor pretreatment on renal allograft
survival. Next, a mannitol infusion administered peroperatively
into the recipient of a donor pretreated allograft (Table 4)
increased diuresis and decreased the renal cortical content of
radioactive carbon, but most of the radioactivity flushed out of
the graft was removed from the liver and bile and not from the
urine. Possibly mannitol mediates this effect by enhancing the
renal flow of lymph [401 which might be related to a decrease in
vascular resistance [41] and thus renal blood flow. Probably the
drugs transplanted within the donor pretreated renal allograft
exert their effects locally because only 0.5% of the cyclophos-
phamide infused resides in the graft. Our donor and recipient
dogs weighed usually between 9 and 10kg which meant that less
than 5 mg of cyclophosphamide and metabolites was given to a
10-kg recipient of which half may be lost into the urine in an
immediate postoperative period. A single dose of 0.25 mg/kg of
microsomally activated cyclophosphamide is unlikely to alter
the immune response by means of a systemic effect, for
example, on T lymphocytes [421. How a local effect is exerted
we do not know, but since carbon 14 cyclophosphamide and its
metabolites appear to diffuse readily through and out of the
renal cortex in order to be secreted into urine and bile in the
first few hours postoperatively, a working hypothesis may be
presented.
We conclude that host lymphocytes entering the cortex of the
renal allograft in the first few hours postoperatively [43] get
sensitized [44] and next relocate into the central lymphoid
organs of the host where they proliferate, as well as host
lymphocytes that enter the renal cortex in the early postopera-
tive period in order to proliferate in the interstitial tissue of the
graft [45] may be subjected to a concentration of cyclophospha-
mide metabolites sufficient to cause an extent of DNA damage
which, in the absence of sufficient time for repair, would
inevitably lead to cell death upon mitosis [46]. The in vitro
observation that a 15-mm period of interaction between lym-
phocyte and allogeneic skin target cell suffices for sensitization
and subsequent proliferation [47], together with the finding that
a 1-hour ex vivo perfusion of host lymphocytes through an
allogeneic kidney suffices for host sensitization [44], supports
such a hypothesis. Donor pretreatment mediating prolonged
canine renal allograft survival appears to be an example of
influencing a biological process by local drug delivery by virtue
of unique properties of the drug and because host sensitization
occurs mainly at the site of the graft.
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